Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients.
<h4>Background</h4>Anaplastic Lymphoma Kinase (ALK) positivity represents a novel molecular target in a subset of Non-Small Cell Lung Cancers (NSCLC). We explore Fluorescence in situ Hybridization (FISH) and Immunohistochemistry (IHC) as diagnostic methods for ALK positive patients and t...
Guardado en:
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/75cb04320c0e4cf28861147ab50dc764 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:75cb04320c0e4cf28861147ab50dc764 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:75cb04320c0e4cf28861147ab50dc7642021-11-18T08:00:09ZFluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients.1932-620310.1371/journal.pone.0052261https://doaj.org/article/75cb04320c0e4cf28861147ab50dc7642013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23359795/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Anaplastic Lymphoma Kinase (ALK) positivity represents a novel molecular target in a subset of Non-Small Cell Lung Cancers (NSCLC). We explore Fluorescence in situ Hybridization (FISH) and Immunohistochemistry (IHC) as diagnostic methods for ALK positive patients and to describe its prevalence and outcomes in a population of NSCLC patients.<h4>Methods</h4>NSCLC patients previously screened for Epidermal Growth Factor Receptor (EGFR) at our institution were selected. ALK positive patients were identified by FISH and the value of IHC (D5F3) was explored.<h4>Results</h4>ninety-nine patients were identified. Median age was 61.5 years (range 35-83), all were caucasians, eighty percent were adenocarcinomas, fifty-one percent were male and thirty-eight percent were current smokers. Seven (7.1%) patients were ALK positive by FISH, thirteen (13.1%) were EGFR mutant, and 65 (65.6%) were negative/Wild Type (WT) for both ALK and EGFR. ALK positivity and EGFR mutations were mutually exclusive. ALK positive patients tend to be younger than EGFR mutated or wt patients. ALK positive patients were predominantly never smokers (71.4%) and adenocarcinoma (71.4%). ALK positive and EGFR mutant patients have a better outcome than negative/WT. All patients with ALK FISH negative tumours were negative for ALK IHC. Out of 6 patients positive for ALK FISH with more tissue available, 5 were positive for ALK IHC and 1 negative.<h4>Conclusions</h4>ALK positive patients represent 7.1% of a population of selected NSCLC. ALK positive patients have different clinical features and a better outcome than EGFR WT and ALK negative patients. IHC is a promising method for detecting ALK positive NSCLC patients.Pablo MartinezJavier Hernández-LosaMa Ángeles MonteroSusana CedrésJosep CastellvíAlex Martinez-MartiNatalia TalladaNuria Murtra-GarrellAlejandro Navarro-MendivillVictor Rodriguez-FreixinosMercedes CanelaSantiago Ramon y CajalEnriqueta FelipPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 1, p e52261 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Pablo Martinez Javier Hernández-Losa Ma Ángeles Montero Susana Cedrés Josep Castellví Alex Martinez-Marti Natalia Tallada Nuria Murtra-Garrell Alejandro Navarro-Mendivill Victor Rodriguez-Freixinos Mercedes Canela Santiago Ramon y Cajal Enriqueta Felip Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. |
| description |
<h4>Background</h4>Anaplastic Lymphoma Kinase (ALK) positivity represents a novel molecular target in a subset of Non-Small Cell Lung Cancers (NSCLC). We explore Fluorescence in situ Hybridization (FISH) and Immunohistochemistry (IHC) as diagnostic methods for ALK positive patients and to describe its prevalence and outcomes in a population of NSCLC patients.<h4>Methods</h4>NSCLC patients previously screened for Epidermal Growth Factor Receptor (EGFR) at our institution were selected. ALK positive patients were identified by FISH and the value of IHC (D5F3) was explored.<h4>Results</h4>ninety-nine patients were identified. Median age was 61.5 years (range 35-83), all were caucasians, eighty percent were adenocarcinomas, fifty-one percent were male and thirty-eight percent were current smokers. Seven (7.1%) patients were ALK positive by FISH, thirteen (13.1%) were EGFR mutant, and 65 (65.6%) were negative/Wild Type (WT) for both ALK and EGFR. ALK positivity and EGFR mutations were mutually exclusive. ALK positive patients tend to be younger than EGFR mutated or wt patients. ALK positive patients were predominantly never smokers (71.4%) and adenocarcinoma (71.4%). ALK positive and EGFR mutant patients have a better outcome than negative/WT. All patients with ALK FISH negative tumours were negative for ALK IHC. Out of 6 patients positive for ALK FISH with more tissue available, 5 were positive for ALK IHC and 1 negative.<h4>Conclusions</h4>ALK positive patients represent 7.1% of a population of selected NSCLC. ALK positive patients have different clinical features and a better outcome than EGFR WT and ALK negative patients. IHC is a promising method for detecting ALK positive NSCLC patients. |
| format |
article |
| author |
Pablo Martinez Javier Hernández-Losa Ma Ángeles Montero Susana Cedrés Josep Castellví Alex Martinez-Marti Natalia Tallada Nuria Murtra-Garrell Alejandro Navarro-Mendivill Victor Rodriguez-Freixinos Mercedes Canela Santiago Ramon y Cajal Enriqueta Felip |
| author_facet |
Pablo Martinez Javier Hernández-Losa Ma Ángeles Montero Susana Cedrés Josep Castellví Alex Martinez-Marti Natalia Tallada Nuria Murtra-Garrell Alejandro Navarro-Mendivill Victor Rodriguez-Freixinos Mercedes Canela Santiago Ramon y Cajal Enriqueta Felip |
| author_sort |
Pablo Martinez |
| title |
Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. |
| title_short |
Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. |
| title_full |
Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. |
| title_fullStr |
Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. |
| title_full_unstemmed |
Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients. |
| title_sort |
fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for alk positive non-small cell lung cancer patients. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/75cb04320c0e4cf28861147ab50dc764 |
| work_keys_str_mv |
AT pablomartinez fluorescenceinsituhybridizationandimmunohistochemistryasdiagnosticmethodsforalkpositivenonsmallcelllungcancerpatients AT javierhernandezlosa fluorescenceinsituhybridizationandimmunohistochemistryasdiagnosticmethodsforalkpositivenonsmallcelllungcancerpatients AT maangelesmontero fluorescenceinsituhybridizationandimmunohistochemistryasdiagnosticmethodsforalkpositivenonsmallcelllungcancerpatients AT susanacedres fluorescenceinsituhybridizationandimmunohistochemistryasdiagnosticmethodsforalkpositivenonsmallcelllungcancerpatients AT josepcastellvi fluorescenceinsituhybridizationandimmunohistochemistryasdiagnosticmethodsforalkpositivenonsmallcelllungcancerpatients AT alexmartinezmarti fluorescenceinsituhybridizationandimmunohistochemistryasdiagnosticmethodsforalkpositivenonsmallcelllungcancerpatients AT nataliatallada fluorescenceinsituhybridizationandimmunohistochemistryasdiagnosticmethodsforalkpositivenonsmallcelllungcancerpatients AT nuriamurtragarrell fluorescenceinsituhybridizationandimmunohistochemistryasdiagnosticmethodsforalkpositivenonsmallcelllungcancerpatients AT alejandronavarromendivill fluorescenceinsituhybridizationandimmunohistochemistryasdiagnosticmethodsforalkpositivenonsmallcelllungcancerpatients AT victorrodriguezfreixinos fluorescenceinsituhybridizationandimmunohistochemistryasdiagnosticmethodsforalkpositivenonsmallcelllungcancerpatients AT mercedescanela fluorescenceinsituhybridizationandimmunohistochemistryasdiagnosticmethodsforalkpositivenonsmallcelllungcancerpatients AT santiagoramonycajal fluorescenceinsituhybridizationandimmunohistochemistryasdiagnosticmethodsforalkpositivenonsmallcelllungcancerpatients AT enriquetafelip fluorescenceinsituhybridizationandimmunohistochemistryasdiagnosticmethodsforalkpositivenonsmallcelllungcancerpatients |
| _version_ |
1718422674753978368 |